Boudes Pol F has filed 5 insider transactions across 2 companies since September 2023.
Most recent transaction: a grant/award of 7500 shares of Protalix BioTherapeutics, Inc. ($PLX) on September 03, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 3, 2025 | Protalix BioTherapeutics, Inc. | $PLX | Boudes Pol F | Not found | A | Common Stock | 7500 | $0.00 | 7,500.0000 | 81,271,610 | 9999.99% | 0.01% |
| Sept. 3, 2025 | Protalix BioTherapeutics, Inc. | $PLX | Boudes Pol F | Not found | A | Stock Options (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 81,271,610 | 9999.99% | 0.02% |
| Jan. 24, 2024 | GALECTIN THERAPEUTICS INC | $GALT | Boudes Pol F | Chief Medical Officer | A | Stock Option (right to buy) | 65000 | $0.00 | 65,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2024 | GALECTIN THERAPEUTICS INC | $GALT | Boudes Pol F | Chief Medical Officer | A | Restricted Stock Unit | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Sept. 29, 2023 | Protalix BioTherapeutics, Inc. | $PLX | Boudes Pol F | Not found | A | Stock Options (Right to Buy) | 61676 | $0.00 | 61,676.0000 | 83,200,641 | 9999.99% | 0.07% |